Beta Alethine in Treating Patients With Myeloma

ClinicalTrials.gov ID: NCT00006466

Public ClinicalTrials.gov record NCT00006466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 11, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma

Study identification

NCT ID: NCT00006466
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: LifeTime Pharmaceuticals; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

beta alethine Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2000
Primary completion: Not listed
Completion: Not listed
Last update posted: Dec 17, 2013

Started 2000

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Emory Clinic	Atlanta	Georgia	30322	—
Victory Over Cancer	Rockville	Maryland	20852	—
St. Vincents Comprehensive Cancer Center	New York	New York	10011	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00006466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 17, 2013 · Synced May 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00006466 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →